1. Home
  2. BWMN vs ORKA Comparison

BWMN vs ORKA Comparison

Compare BWMN & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BWMN
  • ORKA
  • Stock Information
  • Founded
  • BWMN 1995
  • ORKA 2004
  • Country
  • BWMN United States
  • ORKA United States
  • Employees
  • BWMN N/A
  • ORKA N/A
  • Industry
  • BWMN Military/Government/Technical
  • ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • BWMN Consumer Discretionary
  • ORKA Health Care
  • Exchange
  • BWMN Nasdaq
  • ORKA Nasdaq
  • Market Cap
  • BWMN 437.5M
  • ORKA 354.2M
  • IPO Year
  • BWMN 2021
  • ORKA N/A
  • Fundamental
  • Price
  • BWMN $36.13
  • ORKA $14.25
  • Analyst Decision
  • BWMN Strong Buy
  • ORKA Strong Buy
  • Analyst Count
  • BWMN 4
  • ORKA 8
  • Target Price
  • BWMN $36.38
  • ORKA $39.71
  • AVG Volume (30 Days)
  • BWMN 138.1K
  • ORKA 363.4K
  • Earning Date
  • BWMN 08-06-2025
  • ORKA 08-15-2025
  • Dividend Yield
  • BWMN N/A
  • ORKA N/A
  • EPS Growth
  • BWMN N/A
  • ORKA N/A
  • EPS
  • BWMN 0.15
  • ORKA N/A
  • Revenue
  • BWMN $444,588,000.00
  • ORKA N/A
  • Revenue This Year
  • BWMN $16.66
  • ORKA N/A
  • Revenue Next Year
  • BWMN $6.70
  • ORKA N/A
  • P/E Ratio
  • BWMN $245.18
  • ORKA N/A
  • Revenue Growth
  • BWMN 21.78
  • ORKA N/A
  • 52 Week Low
  • BWMN $17.90
  • ORKA $5.49
  • 52 Week High
  • BWMN $37.34
  • ORKA $52.32
  • Technical
  • Relative Strength Index (RSI)
  • BWMN 80.98
  • ORKA N/A
  • Support Level
  • BWMN $31.28
  • ORKA N/A
  • Resistance Level
  • BWMN $33.28
  • ORKA N/A
  • Average True Range (ATR)
  • BWMN 1.26
  • ORKA 0.00
  • MACD
  • BWMN 0.42
  • ORKA 0.00
  • Stochastic Oscillator
  • BWMN 84.86
  • ORKA 0.00

About BWMN Bowman Consulting Group Ltd.

Bowman Consulting Group Ltd is a professional services firm delivering engineering solutions to customers who own, develop, and maintain the built environment. It provides planning, engineering, construction management, commissioning, environmental consulting, geospatial, survey, land procurement, and other technical services to customers operating in a diverse set of end markets. Its services include Civil & Site Engineering, Transportation Engineering, MEP Engineering, Commissioning & Energy Efficiency, Energy Services, Water/Wastewater, Fire Protection, Construction Management, Survey/Geospatial, Environmental Consulting, Structural Engineering, Land Procurement & Right-of-Way, Landscape and Architecture/Planning.

About ORKA Oruka Therapeutics Inc. Common Stock

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Share on Social Networks: